New Research Explores Whether Exercise and Psychedelics Could Be Combined to Treat Depression
Half of all people with major depression do not respond to standard treatment. That statistic has driven researchers to look beyond medications and therapy for new approaches. A new commentary published in Discover Mental Health now makes the case that two of the most promising alternative treatments — exercise and psychedelics — may work even better together than either does alone.
The Problem With Current Treatments
Major depressive disorder affects approximately 290 million people globally. The standard approach relies on antidepressant medications and psychotherapy. Both work for many patients. But research consistently shows that roughly half of people with MDD do not achieve adequate relief from these first line options alone.
That treatment gap has pushed clinicians and researchers toward alternative approaches. Two have gained significant momentum in recent years. Exercise has been adopted as a first line treatment for depression in clinical guidelines worldwide, with efficacy comparable to medications. Psychedelics, particularly psilocybin, have shown rapid and sustained antidepressant effects in clinical trials. The question this commentary asks is simple. What happens when you combine them?
Most clinics spend 4-6 weeks navigating Spravato REMS certification — chasing paperwork, decoding FDA requirements, and wondering if they missed a step. Our AI-powered REMS Certification Assistant cuts that to one sitting. Get a personalized checklist of exactly what you need, and walk into the REMS portal ready to submit.
Get the REMS Certification Assistant →How Exercise Treats Depression
The evidence for exercise as an antidepressant is now substantial. Regular physical activity has a significant protective effect against developing depression. For those already diagnosed, exercise has demonstrated efficacy comparable to antidepressant medications and therapy, with a Number Needed to Treat of just 2. That means for every two people who exercise as treatment, one achieves meaningful improvement.
Exercise works through multiple biological pathways. It increases brain derived neurotrophic factor, a protein critical to neuronal health and plasticity. It boosts hippocampal neurogenesis, the growth of new neurons in the brain region most associated with mood regulation. It also reduces inflammation and improves cardiovascular health, both of which are impaired in depression.
How Psychedelics Treat Depression
Psilocybin has re-emerged as one of the most promising treatments for depression since the early 2000s, when Johns Hopkins researchers revived clinical psychedelic research. Multiple randomized controlled trials have demonstrated rapid and sustained improvements in depressive symptoms after just one or two psilocybin sessions.
Psychedelics work in part by activating serotonin 2A receptors, which triggers a cascade of neuroplastic changes. They acutely boost BDNF signaling and increase glutamate release. They also appear to disrupt the default mode network, a brain circuit associated with rumination and self referential thinking. That disruption may allow patients to break free from entrenched depressive thought patterns.
The Synergy Argument
The commentary’s central argument is that exercise and psychedelics are not just two separate treatments that happen to work. They target overlapping and complementary biological pathways in ways that could amplify each other’s effects.
The BDNF connection is the clearest example. Psychedelics produce an acute spike in BDNF, particularly in the cortex. Exercise produces sustained BDNF elevation over time, particularly in the hippocampus. Combined, they could create both immediate and long lasting neurotrophic support across multiple brain regions. The authors describe this as complementary rather than redundant.
Neuroplasticity tells a similar story. Psychedelics enhance cortical plasticity, while exercise drives hippocampal neurogenesis. Depression involves deficits in both regions. A combined approach could address the full scope of neuroplastic impairment rather than targeting just one area.
The Behavioral Feedback Loop
Beyond biology, the authors highlight a practical synergy. Depression makes it hard to exercise. Low motivation, fatigue, and anhedonia are core symptoms that directly undermine physical activity. Psychedelic experiences have been shown in some studies to increase motivation, connectedness, and openness to new behaviors.
If a psychedelic session can break through the motivational barrier, patients may find it easier to start and maintain an exercise routine. That routine then sustains the neurobiological benefits. The result is a positive feedback loop that neither intervention could easily create alone.
What This Means for Patients and Clinics
This is a commentary and mechanistic review, not a clinical trial. No patients were enrolled. No combined protocol has been formally tested. The authors are explicit that clinical trials are needed before any treatment recommendations can be made.
That said, the implications are significant. Clinics already offering psychedelic assisted therapy could explore structured exercise programming as a complement. Patients completing a psilocybin or ketamine series could be encouraged to establish exercise habits during the neuroplasticity window that follows treatment. The integration does not require a new drug or a new technology. It requires intentional protocol design.
The Bottom Line
Exercise and psychedelics each work for depression. The biological evidence suggests they may work better together. This commentary from Discover Mental Health lays out the mechanistic case and calls for the clinical trials that would prove it. For the half of depression patients who do not respond to current treatments, that research cannot come soon enough.
